Roche Diabetes Care Canada Receives Well being Canada Authorization for the Accu-Chek® Information Hyperlink Blood Glucose Meter with Wi-fi Connectivity

• Through an agreement between Roche Diabetes Care and Medtronic Canada, Accu-Chek Guide Link is a state-of-the-art blood glucose meter designed exclusively for connection to the Medtronic MiniMedTM 770G insulin pump system.

• The Accu-Chek Guide Link can deliver seamless and high-precision automated wireless results directly to the MiniMedTM 770G to aid in the continued adequate delivery of insulin to people with type 1 diabetes in people aged two and over.

LAVAL, QC, June 14, 2021 / CNW / – Roche Diabetes Care Canada is pleased to announce that it has received Health Canada approval for the Accu-Chek Guide Link blood glucose meter, Roche Diabetes Care’s latest innovation to help Canadians with type 1 diabetes to control your health and worry less about daily therapy routines.

Roche logo (CNW Group / Roche Diabetes Care)

This state-of-the-art blood glucose meter can only be combined with the Medtronic MiniMedTM 770G – the only insulin pump system in Canada that offers an adaptive basal insulin delivery every 5 minutes for patients 2 years and older, with the additional benefits of smartphone connectivity. A pump system connected to the smartphone enables patients and their caregivers to remotely view glucose and insulin data on a smartphone and automatically share them with their doctor to optimize their diabetes management. Accurate test results from the meter are wirelessly sent to the pump system for quick sensor calibration and aiding in insulin adjustment.

This represents a breakthrough for insulin pump users that will help Canadians living with diabetes achieve greater freedom and better health.

“At Roche Diabetes Care, our vision is to help people with diabetes think less about their daily diabetes and focus more on their lives, which is why we are excited to bring this new innovation to market Canada to better serve the diabetes community, “said Jade Dagher, Head of the Canada Sub-Region, Australia & New Zealand. “Roche Diabetes Care’s partnership with Medtronic is a significant advancement for insulin pump users and fulfills our promise to provide integrated patient-centered care solutions that help people with diabetes.”

The story goes on

The Accu-Chek Guide Link has been approved based on clinical studies demonstrating its quick and accurate blood glucose readings that even exceed standards of accuracy.1 This is especially important for people with diabetes on insulin therapy, as reliable and accurate blood glucose readings are essential Make the right therapy decisions and need the insulin dosage. 2,3

Roche Diabetes Care is excited that this new innovation will help Canadians with diabetes simplify their diabetes management. The Accu-Chek Guide Link System is now available exclusively for people with type 1 diabetes aged two and over using the Medtronic MiniMedTM 770G insulin pump system. People with diabetes and caregivers should speak to their doctor or diabetes care provider to determine if this product is suitable for them.

About Roche Diabetes Care

Roche Diabetes Care has pioneered innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and high-risk patients to achieve more time in their target areas and to experience real relief from everyday therapy.

As the global leader in integrated personalized diabetes management (iPDM), Roche Diabetes Care works with thought leaders around the world, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care has set itself the goal of transforming and improving care and promoting sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, consisting of glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care and its partners combine patient-oriented added value. By building and working together in an open ecosystem, connecting devices and digital solutions, and contextualizing relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, resulting in personalized and effective therapy adjustments. For better results and real relief.

MySugr, one of the most popular diabetes management apps, has been part of Roche Diabetes Care since 2017.

More information is available at www.rochediabetes.com, www.accu-chek.ca.

About Roche

Roche is a global pharmaceutical and diagnostics pioneer focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the market leader in personalized medicine – a strategy that aims to tailor the right treatment to each patient in the best possible way.

Roche is the world’s largest biotech company with truly differentiated drugs in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also a global leader in in vitro diagnostics and tissue-based cancer diagnostics and a pioneer in diabetes management.

Founded in 1896, Roche continues to seek better ways to prevent, diagnose and treat disease and make a sustainable contribution to society. In addition, the company aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty drugs developed by Roche are on the World Health Organization’s Essential Medicines List, including life-saving antibiotics, antimalarials and cancer drugs. In addition, Roche was named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI) for the eleventh time in a row.

The Roche Group based in Basel, Switzerland, is active in over 100 countries and employed around 98,000 people worldwide in 2019. Roche invested in 2019 11.7 billion francs in R&D and reported sales of CHF 61.5 billion. Genentech, in The United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan. More information is available at www.roche.com.

All trademarks used or mentioned in this press release are protected by law.

References:

_________________________

SOURCE Roche Diabetes Care

Cision

To download multimedia, see the original content at: http://www.newswire.ca/en/releases/archive/June2021/14/c4528.html